Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hair Loss Clear all
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

NCT07133308
View directory record Official record
Conditions
Alopecia Areata
Interventions
Deuruxolitinib, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling

NCT04342091
View directory record Official record
Conditions
Fibrosing Alopecia, Frontal Fibrosing Alopecia, Central Centrifugal Cicatricial Alopecia
Interventions
SOL Nova Device
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Utility of Platelet Rich Plasma in Hair Loss

NCT03376581
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Platelet rich plasma
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Jul 21, 2026, 11:24 AM EDT
Active, not recruiting No phase listed Observational

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
54
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Active, not recruiting No phase listed Observational

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

NCT07226531
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

NCT02018042
View directory record Official record
Conditions
Alopecia Areata
Interventions
Abatacept
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jul 21, 2026, 11:24 AM EDT
Not listed Not applicable Interventional

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata

NCT03078686
View directory record Official record
Conditions
Alopecia Areata, Scarring Alopecia
Interventions
tSVF by lipoaspiration, PRP Concentration, Emulsification tSVF, cSVF isolation and concentration, cSVF in Normal Saline IV
Procedure
Lead sponsor
Regeneris Medical
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Irvine, California • North Attleboro, Massachusetts • Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

NCT04435847
View directory record Official record
Conditions
Male Pattern Hair Loss
Interventions
HST 001, Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
25 Years to 55 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

NCT01023841
View directory record Official record
Conditions
Eyelash Hypotrichosis, Alopecia Areata
Interventions
bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
CB-03-01 solution, Minoxidil Solution 5%, Placebo solution
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 21, 2026, 11:24 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of VDPHL01 in Males With AGA

NCT06724614
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Early Phase 1 Interventional

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668
View directory record Official record
Conditions
Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
Interventions
Topical gabapentin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 21, 2026, 11:24 AM EDT
Recruiting Phase 2 Interventional

Regeneron AA Multicenter (Dupilumab)

NCT05551793
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Irvine, California • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Terminated Phase 2 Interventional Results available

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

NCT04517864
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Childhood Alopecia Areata Study Using the 308-nm Excimer Laser

NCT01736007
View directory record Official record
Conditions
Alopecia Areata
Interventions
308-nm excimer laser to alopecia patch, Liquid light guide tip on laser
Device
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Study of Axillary Hair Loss in Patients Treated With the miraDry System

NCT01732497
View directory record Official record
Conditions
Underarm Hair
Interventions
miraDry Treatment
Device
Lead sponsor
Miramar Labs
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Edina, Minnesota • New York, New York • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Early Phase 1 Interventional Results available

Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis

NCT03491267
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Retinoic acid, Laser, Sham treatment, Sham treatment
Drug · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Not applicable Interventional Results available

Hair Loss Prevention Study for Pancreatic Cancer

NCT04492800
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling Device
Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

NCT01111981
View directory record Official record
Conditions
Alopecia
Interventions
Clobetasol Propionate 0.05% Emollient Foam
Drug
Lead sponsor
Callender Center for Clinical Research
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mitchellville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata

NCT02684097
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Jul 21, 2026, 11:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

NCT06340360
View directory record Official record
Conditions
Alopecia Areata
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 11:24 AM EDT